Clinical trial
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating…
NCT00275054 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00275054 |
|---|---|
| Title | Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia |
| Official title | Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | Fludarabine, Cyclophosphamide, Rituximab |
| Enrollment | 825 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jun 1, 2015 |
| First posted | Jan 11, 2006 |
| Last update posted | May 23, 2019 |
| Countries | Austria, France, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: